Skip to content

Feasibility Trial of the Bios Device for Continuous Glucose Monitoring

A Clinical Feasibility Study of the Bios Device for Continuous Glucose Monitoring in Subjects With Type 1 or Type 2 Diabetes Mellitus

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04226846
Enrollment
50
Registered
2020-01-13
Start date
2019-12-09
Completion date
2020-03-15
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes, Type 2 Diabetes

Brief summary

The study is an open-label, prospective, within-subject comparison of the Bios device readings versus venous blood sample glucose readings, glucose readings from a Dexcom CGM and an SMBG device in subjects previously diagnosed with Type 1 or Type 2 diabetes mellitus.

Interventions

None listed

Sponsors

GraphWear Technologies Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subject is at least 18 years of age; 2. Subject has had a diagnosis of diabetes mellitus either Type I or Type II; 3. For insulin-using subjects only: subject will not inject insulin or wear an insulin pump insertion set within a 10 cm distance of any Bios device; 4. Subject able to wear multiple CGM devices simultaneously; 5. Subject is either a patient diagnosed with Type I diabetes mellitus currently wearing a Dexcom CGM device or a patient diagnosed with Type II diabetes mellitus who will agree to use a Dexcom CGM device during participation in the study. There are no restrictions on the model of the Dexcom CGM device. 6. Subject agrees to provide a log of medications (prescription and over-the-counter) and dietary supplements (e.g., vitamins) taken during the study period, including dosage; 7. Subject has a smart device that complies with the requirements listed in Attachment 1 of this protocol and is willing to download and run the GraphWear Patient application on their device; 8. Subject is able to read and understand the Informed Consent Form and has voluntarily provided written informed consent; 9. In the Principal Investigator's opinion, subject is able to be compliant with provisions laid out in this protocol.

Exclusion criteria

1. Subjects with any physical or behavioral disorder, which, in the opinion of the Principal Investigator, may interfere with the use of the device or compliance with the study protocol; 2. Subject has any of the following: * a skin condition that precludes wearing of the device; * a known allergy that precludes wearing of the device; * tattoos or other skin alterations that may interfere with device placement and/or operation; 3. History of substance abuse within 6 months of study start; 4. Use of any illicit drugs during the duration of the study period; 5. Marijuana use during the duration of the study period; 6. If female, subject is pregnant or nursing; 7. Subject is on active dialysis; 8. Subjects whom the Principal Investigator believes may not be an appropriate candidate for this device.

Design outcomes

Primary

MeasureTime frameDescription
Comparison between Bios device readings and glucose values2 weeksThe primary objective of this study is to compare the glucose measurements collected by the Bios device to glucose values measured with a blood glucose lab analyzer (e.g., YSI), glucose values obtained with a self-monitoring blood glucose device (SMBG) and readings from the Dexcom System in subjects previously diagnosed with Type 1 or Type 2 diabetes mellitus.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026